01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of...
Pearce IP BioBlast w/e 04 February 2022
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP...
Pearce IP BioBlast® f/e 31 January 2022
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common...
Pearce IP BioBlast® w/e 14 January 2022
10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration,...
Pearce IP BioBlast® w/e 07 January 2022
30 Dec 21 | US | Biocon Biologics announced that the US Court of Appeals for the Federal Circuit Court has upheld the...
Pfizer quest for Samsung Bioepis etanercept documents continues
Shortly before Christmas, the judgment handed down by Justice Burley on 18 November 2021 on a second preliminary...
Pearce IP BioBlast® 31 December 2021
20 Dec 21 | US | Sandoz announced that it has submitted a BLA to the FDA for a proposed biosimilar trastuzumab. 20 Dec...
PTE Alert (part 2): Bad Patent Term Extension Enables Generics to Avoid Preliminary Injunction in Australia
Newly appointed Justice Rofe delivered an early Christmas gift for generic and biosimilar companies in Australia in...
Pearce IP BioBlast® w/e 17 December 2021
11 Dec 21 | Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I...
PTE Alert – interlocutory injunction refused in Tecfidera® dispute
In early November Pearce IP reported on a number of Federal Court decisions which appear to indicate flaws in the...
Pearce IP BioBlast® w/e 10 December 2021
06 Dec 21 | AU | Australia’s TGA provisionally approved Celltrion’s Regkirona® (regdanvimab) for the treatment of...
Full Court finds another computer-implemented scheme unpatentable
Repipe Pty Ltd v Commissioner of Patents (No 3) [2021] FCA 31: Repipe Pty Ltd v Commissioner of Patents [2021] FCAFC 223
Date: 29 January 2021 Court: Federal Court of Australia Judge: McKerracher J Date: 08 December 2021 Court: Full Court...
Vague proposals do not an inventor make
Vehicle Monitoring Systems Pty Ltd v SARB Management Group Pty Ltd [2021] FCAFC 224
Date: 08 December 2021Court: Full Court of the Federal Court of AustraliaJudges: Nicholas, Yates and O'Bryan JJ...
Pearce IP BioBlast® w/e 03 December 2021
01 Dec 21 | CN | Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the...
Pearce IP BioBlast® w/e 26 November 2021
21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar)...